Shares in Axovant Sciences Ltd sank almost 50 percent after investors shrank back on new of the failure of lead drug intepirdine in a mid-stage study in patients with a particular kind of dementia. The company said the investigational drug did not meet its primary efficacy endpoints in the Phase IIb HEADWAY and pilot Phase II Gait and Balance studies, which assessed its potential in patients with patients with dementia with Lewy bodies (DLB). In the HEADWAY study, neither 35mg or 70mg dose of in...
READ MORE
|
Could U.S. patient groups be warming up to pharma? Skepticism seems to be on the wane at least by some measures, according to PatientView’s annual corporate reputation study.Patient groups in the U.S. rated pharma companies’ patient-centricity, integrity and patient group partnerships much higher in this year's study, which compared 2017 to 2016. Ratings increased 10% or more in each category, while patient-centricity jumped the most last year—to 43%, up from 24% in 2016. S...
FIERCEPHARMA
READ MORE
|
The EpiPen generic Mylan promised in August amid a pricing firestorm is officially on its way to market.The product—priced at $300 per two-pack, less than half the branded med’s list price—will hit pharmacy shelves next week, Mylan said.The EpiPen copycat is a solution Mylan pledged after Congressional questions about its pricing—which has gone from $100 in 2008 to more than $600—ignited public outcry. Industry watchers, including Wells Fargo analyst David Maris, labeled the copay assistance Myl...
FIERCEPHARMA.COM
READ MORE
|
GlaxoSmithkline has turned down options to take on board Ionis Pharmaceuticals' experimental antisense therapies inotersen and IONIS-FB-LRx following a pipeline revamp. Inotersen is being developed for patients with TTR amyloidosis (ATTR), a rare disease caused by the build-up of amyloid within the tissues of the body damaging the structure and the function of the organs affected. Ionis said it recently completed a Phase III trial of inotersen demonstrating its “significant benefit” on both prim...
READ MORE
|
The FDA has granted Fast Track designation to Shire's SHP607 for the prevention of chronic lung disease in extremely premature infants. SHP607, currently in phase 2 clinical development, is a recombinant human version of the naturally occurring protein complex of insulin-like growth factor 1 (IGF-1) and its most abundant binding protein, IGF binding protein-3 (IGFBP-3). IGF-1 plays an important role in the development of the fetus in the uterus....
READ MORE
|
Peak Analysis & Automation (PAA), a global leader in laboratory automation, announces the launch of its S-LAB™ automated plate handler on stand B15 at ELRIG Drug Discovery, ACC Liverpool, October 3-4th 2017. Breaking the mold of traditional solutions to make it easier for labs to automate, S-LAB is an easy-to-use, compact, and affordable single instrument loading solution, with the same reliability as a robotic arm....
READ MORE
|